Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2021-08-26 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
北京双鹭药业股份有限公司关于公司证券事务代表辞职的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the resignation of the company's securities affairs representative. It details the resignation, the effective date, and the company's plan to appoint a replacement. There is no financial data, no report attached or referenced, and no mention of financial results or regulatory filings beyond the resignation notice. This fits the category of Board/Management Information (MANG), as it concerns a change in a key company representative related to governance and management roles.
2021-08-26 Chinese
2021年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2021 半年度报告摘要' which translates to '2021 Half-Year Report Summary'. It contains detailed financial data such as revenue, net profit, cash flow, and shareholder information for the half-year period. It also includes management discussion on business performance and important events during the period. The document length is 4170 characters, which is relatively short but contains substantive financial data and analysis, not just an announcement or summary notice. The content matches the characteristics of an Interim / Quarterly Report (IR), which covers a period shorter than a full fiscal year and includes actual financial statements and analysis. Therefore, the document should be classified as an Interim / Quarterly Report (IR). H1 2021
2021-08-26 Chinese
北京双鹭药业股份有限公司奥硝唑注射液（遁宁R）通过一致性评价的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval of a pharmaceutical product (奥硝唑注射液) passing a regulatory consistency evaluation by the National Medical Products Administration of China. It contains no financial statements, no management discussion of financial results, no voting results, no executive changes, no earnings data, and no mention of any report filings. The document is an official announcement about a regulatory approval event affecting the company's product portfolio and market position. It is not a report, transcript, or financial filing. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2021-08-05 Chinese
北京双鹭药业股份有限公司关于参股公司首次公开发行股票并在科创板上市的申请通过上市委审议的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (777 characters) from Beijing SL Pharmaceutical Co., Ltd. regarding the approval of a related company's initial public offering (IPO) and listing on the STAR Market (科创板). It includes details about shareholding percentages and references a previous announcement. The document does not contain financial statements or detailed financial analysis but serves as a regulatory disclosure about the IPO progress and shareholding. It is an official announcement related to capital market activity but not a full financial report or earnings release. Given the short length and nature of the content, it fits best as a Regulatory Filing (RNS) rather than a Capital/Financing Update (CAP) or other categories. The document is not a report itself but a regulatory announcement about the IPO process and shareholding status.
2021-08-03 Chinese
北京双鹭药业股份有限公司关于第二大股东部分股权解除质押的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement regarding the partial release of pledged shares by the company's second largest shareholder. It details the number of shares released from pledge, the shareholder involved, and related registration procedures. There is no financial data, no report attached or referenced as being published, and no mention of meetings or voting results. The content fits the category of announcements related to share pledges and capital structure changes but does not describe new share issuance or buybacks. This aligns best with a Capital/Financing Update (CAP) filing type, which covers updates on financing activities or capital structure changes such as share pledges or releases.
2021-07-29 Chinese
北京双鹭药业股份有限公司关于公司第二大股东非公开发行可交换公司债券换股进展暨换股导致权益变动比例超过1%的公告
Major Shareholding Notification Classification · 95% confidence The document is an official announcement from Beijing SL Pharmaceutical Co., Ltd. regarding the progress of convertible bond exchange by the company's second largest shareholder and the resulting change in equity proportion exceeding 1%. It details the shareholding changes, bond issuance background, exchange price adjustments, and compliance with securities laws. The document is focused on notifying shareholders and the market about a significant shareholding change due to bond conversion, which affects ownership percentages but does not change the controlling shareholder or actual controller. It is not a financial report, earnings release, or management discussion, but a regulatory disclosure about a major shareholding change. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length is under 5,000 characters and contains detailed shareholding change data, not just a brief announcement or a certification, so it is not RNS or RPA. Hence, the classification is MRQ with high confidence.
2021-06-29 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.